CN103080106A - 用作激酶抑制剂的环醚化合物 - Google Patents
用作激酶抑制剂的环醚化合物 Download PDFInfo
- Publication number
- CN103080106A CN103080106A CN2011800335423A CN201180033542A CN103080106A CN 103080106 A CN103080106 A CN 103080106A CN 2011800335423 A CN2011800335423 A CN 2011800335423A CN 201180033542 A CN201180033542 A CN 201180033542A CN 103080106 A CN103080106 A CN 103080106A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- amino
- equiv
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *C(C(NC(*)=O)=*)=**=* Chemical compound *C(C(NC(*)=O)=*)=**=* 0.000 description 16
- LFKDJXLFVYVEFG-UHFFFAOYSA-N CC(C)(C)OC(N)=O Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- ONVIACLNWQFOBK-UHFFFAOYSA-N CC(C)(C)[N](C)(C)C Chemical compound CC(C)(C)[N](C)(C)C ONVIACLNWQFOBK-UHFFFAOYSA-N 0.000 description 1
- OVQBFHCEJVOYQI-XBBDIZMDSA-N CC(C)(C)[SiH](C)O[C@@H](C[C@H](c(ccnc1)c1[N+]([O-])=O)OC1(C)C)[C@@H]1O Chemical compound CC(C)(C)[SiH](C)O[C@@H](C[C@H](c(ccnc1)c1[N+]([O-])=O)OC1(C)C)[C@@H]1O OVQBFHCEJVOYQI-XBBDIZMDSA-N 0.000 description 1
- BMWPFULBEJVQQV-FKYLOJIBSA-N CC(C)NC(c(cc1)cc(/C(/N=C(\C)/C(O)=O)=C(/C=C)\F)c1F)=O Chemical compound CC(C)NC(c(cc1)cc(/C(/N=C(\C)/C(O)=O)=C(/C=C)\F)c1F)=O BMWPFULBEJVQQV-FKYLOJIBSA-N 0.000 description 1
- OPTPSSHEDGAJPW-LVQVYYBASA-N CC(C)[C@H]([C@H]([C@@H](C1)NC(OC(C)(C)C)=O)O)O[C@H]1c(ccnc1)c1N Chemical compound CC(C)[C@H]([C@H]([C@@H](C1)NC(OC(C)(C)C)=O)O)O[C@H]1c(ccnc1)c1N OPTPSSHEDGAJPW-LVQVYYBASA-N 0.000 description 1
- WIOOTLXLCLDKHK-UHFFFAOYSA-N CC(CC(F)=C1C2NC(C(O)=O)=CC=C2F)C=C1F Chemical compound CC(CC(F)=C1C2NC(C(O)=O)=CC=C2F)C=C1F WIOOTLXLCLDKHK-UHFFFAOYSA-N 0.000 description 1
- FQNFACTVEIYKRG-BLLLJJGKSA-N CC(O[C@@H](CC1)C[C@H](c(ccnc2)c2[N+]([O-])=O)OC(C2CC2)=C1O)=O Chemical compound CC(O[C@@H](CC1)C[C@H](c(ccnc2)c2[N+]([O-])=O)OC(C2CC2)=C1O)=O FQNFACTVEIYKRG-BLLLJJGKSA-N 0.000 description 1
- QYLSMOGZIFJERJ-UPJWGTAASA-N CC(O[C@@H]1C=C(c(ccnc2)c2[N+]([O-])=O)O[C@H](CO)[C@H]1O)=O Chemical compound CC(O[C@@H]1C=C(c(ccnc2)c2[N+]([O-])=O)O[C@H](CO)[C@H]1O)=O QYLSMOGZIFJERJ-UPJWGTAASA-N 0.000 description 1
- JFFOTTSQJLRENT-UHFFFAOYSA-N CC1(C)OB(c(c(F)c(cc2)C(N(C)C)=O)c2F)OC1(C)C Chemical compound CC1(C)OB(c(c(F)c(cc2)C(N(C)C)=O)c2F)OC1(C)C JFFOTTSQJLRENT-UHFFFAOYSA-N 0.000 description 1
- IQFXJRXOTKFGPN-UHFFFAOYSA-N CCN(CC)C=C Chemical compound CCN(CC)C=C IQFXJRXOTKFGPN-UHFFFAOYSA-N 0.000 description 1
- MBBOTGYURVQWIF-UHFFFAOYSA-N CCOC(C1=CNC=C(c2ccccc2)C1=O)=O Chemical compound CCOC(C1=CNC=C(c2ccccc2)C1=O)=O MBBOTGYURVQWIF-UHFFFAOYSA-N 0.000 description 1
- BETFDCJHMAIVBA-FGRDXJNISA-N CC[C@@H](C(C)(C)[C@H](C1)OC(C)=O)OC1c(ccnc1)c1N Chemical compound CC[C@@H](C(C)(C)[C@H](C1)OC(C)=O)OC1c(ccnc1)c1N BETFDCJHMAIVBA-FGRDXJNISA-N 0.000 description 1
- JXIIMQNBQLSHOU-UPJWGTAASA-N CC[C@H]([C@H](C(C1)=O)O)O[C@H]1c1cc[n+](C)cc1[N+]([O-])=O Chemical compound CC[C@H]([C@H](C(C1)=O)O)O[C@H]1c1cc[n+](C)cc1[N+]([O-])=O JXIIMQNBQLSHOU-UPJWGTAASA-N 0.000 description 1
- UGHMFWGLAWDMBT-UHFFFAOYSA-N COC(c(cc(c(F)c1)Br)c1N)=[O]=C Chemical compound COC(c(cc(c(F)c1)Br)c1N)=[O]=C UGHMFWGLAWDMBT-UHFFFAOYSA-N 0.000 description 1
- LJCMMKJELAPZOV-NURSFMCSSA-N C[C@@H]1C[C@H](c(ccnc2)c2N)O[C@H](COC(C)=O)C1 Chemical compound C[C@@H]1C[C@H](c(ccnc2)c2N)O[C@H](COC(C)=O)C1 LJCMMKJELAPZOV-NURSFMCSSA-N 0.000 description 1
- GIQDCNUEJAQFKV-ZYOFANERSA-N C[C@H](C[C@H](c(ccnc1)c1N)O[C@@H]1C)[C@]1(CCCNCc1ccccc1)O Chemical compound C[C@H](C[C@H](c(ccnc1)c1N)O[C@@H]1C)[C@]1(CCCNCc1ccccc1)O GIQDCNUEJAQFKV-ZYOFANERSA-N 0.000 description 1
- SUVSELFSHADBRK-DNSOKLHBSA-N C[C@H]([C@@H](C)O[C@H](C1)c(ccnc2)c2[N+]([O-])=O)C1=O Chemical compound C[C@H]([C@@H](C)O[C@H](C1)c(ccnc2)c2[N+]([O-])=O)C1=O SUVSELFSHADBRK-DNSOKLHBSA-N 0.000 description 1
- KKSJFQHGMKIASG-JGMGGLLFSA-N C[C@H]([C@H](C)[C@H](c(ccnc1)c1N)O[C@@H]1C)[C@@H]1O Chemical compound C[C@H]([C@H](C)[C@H](c(ccnc1)c1N)O[C@@H]1C)[C@@H]1O KKSJFQHGMKIASG-JGMGGLLFSA-N 0.000 description 1
- UPHGJVUWCRGOKV-KDYMROGCSA-N C[C@H]([C@](C)([C@@H](C1)NC(OC(C)(C)C)=O)O)O[C@H]1c(ccnc1)c1NC(c(cc1)nc(-c(c(F)cc(C(N(C)C)=O)c2)c2F)c1F)=O Chemical compound C[C@H]([C@](C)([C@@H](C1)NC(OC(C)(C)C)=O)O)O[C@H]1c(ccnc1)c1NC(c(cc1)nc(-c(c(F)cc(C(N(C)C)=O)c2)c2F)c1F)=O UPHGJVUWCRGOKV-KDYMROGCSA-N 0.000 description 1
- RLCXIBVIZKXIJT-PTERYMMESA-N C[C@H]([C@](C)([C@@H]([C@H]1F)O[Si](C)(C)C(C)(C)C)O)O[C@H]1c(ccnc1)c1N Chemical compound C[C@H]([C@](C)([C@@H]([C@H]1F)O[Si](C)(C)C(C)(C)C)O)O[C@H]1c(ccnc1)c1N RLCXIBVIZKXIJT-PTERYMMESA-N 0.000 description 1
- HIAKCJKIVLUYBM-CQSZACIVSA-N C[Si+](C)(C)OC(C1)=CC2(CC2)O[C@H]1c(ccnc1)c1[N+]([O-])=O Chemical compound C[Si+](C)(C)OC(C1)=CC2(CC2)O[C@H]1c(ccnc1)c1[N+]([O-])=O HIAKCJKIVLUYBM-CQSZACIVSA-N 0.000 description 1
- MRPYPHHGUGOGSY-BHDDXSALSA-N N#CC[C@H]([C@H](CC1)O)O[C@H]1c(ccnc1)c1NC(c(cc1)nc(-c(c(F)ccc2)c2F)c1C#N)=O Chemical compound N#CC[C@H]([C@H](CC1)O)O[C@H]1c(ccnc1)c1NC(c(cc1)nc(-c(c(F)ccc2)c2F)c1C#N)=O MRPYPHHGUGOGSY-BHDDXSALSA-N 0.000 description 1
- LBASYCNGLJOSSX-PWRODBHTSA-N N#CC[C@H]([C@H](CC1)O)O[C@H]1c(ccnc1)c1NC(c(cc1)nc(-c(c(F)ccc2)c2F)c1F)=O Chemical compound N#CC[C@H]([C@H](CC1)O)O[C@H]1c(ccnc1)c1NC(c(cc1)nc(-c(c(F)ccc2)c2F)c1F)=O LBASYCNGLJOSSX-PWRODBHTSA-N 0.000 description 1
- PUKAYQCYGUDRAY-UHFFFAOYSA-N Nc1c(C2OCCCO2)ccnc1 Chemical compound Nc1c(C2OCCCO2)ccnc1 PUKAYQCYGUDRAY-UHFFFAOYSA-N 0.000 description 1
- JAOQUSFIYPHIMC-XCBNKYQSSA-N Nc1c([C@H](CC2)OC[C@@H]2O)ccnc1 Chemical compound Nc1c([C@H](CC2)OC[C@@H]2O)ccnc1 JAOQUSFIYPHIMC-XCBNKYQSSA-N 0.000 description 1
- FPAYBPUGCOPLJM-UHFFFAOYSA-N Nc1ccc(C2=NCCS2)nc1C(O)=O Chemical compound Nc1ccc(C2=NCCS2)nc1C(O)=O FPAYBPUGCOPLJM-UHFFFAOYSA-N 0.000 description 1
- WCRMEZPWARIASK-UHFFFAOYSA-N Nc1cnc(-c(cccc2)c2F)nc1C(O)O Chemical compound Nc1cnc(-c(cccc2)c2F)nc1C(O)O WCRMEZPWARIASK-UHFFFAOYSA-N 0.000 description 1
- AXXUKMYAQJKPMI-UHFFFAOYSA-N Nc1ncc(-c2ccccc2)nc1C(O)=O Chemical compound Nc1ncc(-c2ccccc2)nc1C(O)=O AXXUKMYAQJKPMI-UHFFFAOYSA-N 0.000 description 1
- GOHIYTWEZLRECD-UHFFFAOYSA-N [O-][N+](c(cncc1)c1C(C(F)(F)F)=O)=O Chemical compound [O-][N+](c(cncc1)c1C(C(F)(F)F)=O)=O GOHIYTWEZLRECD-UHFFFAOYSA-N 0.000 description 1
- CYMVNIANTHCYSU-UHFFFAOYSA-N [O-][N+](c1c(C(C2)(C(F)(F)F)OC=CC2=O)ccnc1)=O Chemical compound [O-][N+](c1c(C(C2)(C(F)(F)F)OC=CC2=O)ccnc1)=O CYMVNIANTHCYSU-UHFFFAOYSA-N 0.000 description 1
- QJUWWYDQJRXUDO-LDYMZIIASA-N [O-][N+](c1c([C@@H](C2)OC3(CC3)C[C@@H]2O)ccnc1)=O Chemical compound [O-][N+](c1c([C@@H](C2)OC3(CC3)C[C@@H]2O)ccnc1)=O QJUWWYDQJRXUDO-LDYMZIIASA-N 0.000 description 1
- DVXFDLWDPGTTSL-CYBMUJFWSA-N [O-][N+](c1c([C@@H](C2)OCCCCCC2=O)ccnc1)=O Chemical compound [O-][N+](c1c([C@@H](C2)OCCCCCC2=O)ccnc1)=O DVXFDLWDPGTTSL-CYBMUJFWSA-N 0.000 description 1
- UDQMAEUWUGSYAO-OASPWFOLSA-N [O-][N+](c1c([C@@H](C2)O[C@H](CCC3)[C@H]3C2=O)ccnc1)=O Chemical compound [O-][N+](c1c([C@@H](C2)O[C@H](CCC3)[C@H]3C2=O)ccnc1)=O UDQMAEUWUGSYAO-OASPWFOLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36175510P | 2010-07-06 | 2010-07-06 | |
| US61/361,755 | 2010-07-06 | ||
| PCT/EP2011/061198 WO2012004217A1 (en) | 2010-07-06 | 2011-07-04 | Cyclic ether compounds useful as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103080106A true CN103080106A (zh) | 2013-05-01 |
Family
ID=44279730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011800335423A Pending CN103080106A (zh) | 2010-07-06 | 2011-07-04 | 用作激酶抑制剂的环醚化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20130109682A1 (enExample) |
| EP (1) | EP2590968A1 (enExample) |
| JP (1) | JP2013530199A (enExample) |
| CN (1) | CN103080106A (enExample) |
| WO (1) | WO2012004217A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106795151A (zh) * | 2014-08-06 | 2017-05-31 | 诺华股份有限公司 | 蛋白激酶c抑制剂和它们的使用方法 |
| CN110713476A (zh) * | 2019-11-07 | 2020-01-21 | 河南中烟工业有限责任公司 | 一种2,3-二氢-3,5-二羟基-6-甲基-4h-吡喃-4-酮的合成方法 |
| CN110790737A (zh) * | 2019-11-07 | 2020-02-14 | 河南中烟工业有限责任公司 | 一种2,3-二氢-3,5-二羟基-6-乙基-4h-吡喃-4-酮的制备方法 |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105360132A (zh) | 2010-11-03 | 2016-03-02 | 陶氏益农公司 | 杀虫组合物和与其相关的方法 |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| UY33930A (es) * | 2011-03-04 | 2012-10-31 | Novartis Ag | Inhibidores novedosos de quinasas |
| ES2671748T3 (es) | 2011-07-21 | 2018-06-08 | Tolero Pharmaceuticals, Inc. | Inhibidores heterocíclicos de proteína quinasas |
| ES2899850T3 (es) | 2011-10-26 | 2022-03-15 | Corteva Agriscience Llc | Composiciones plaguicidas y procedimientos relacionados con las mismas |
| US9708288B2 (en) | 2012-04-27 | 2017-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| MX2014013069A (es) | 2012-04-27 | 2015-07-06 | Dow Agrosciences Llc | Composiciones plaguicidas y procesos relacionados. |
| US9282739B2 (en) | 2012-04-27 | 2016-03-15 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| CN104334546B (zh) | 2012-05-21 | 2017-05-03 | 诺华股份有限公司 | 作为激酶抑制剂的新的环‑取代的n‑吡啶基酰胺 |
| UA125503C2 (uk) | 2012-06-13 | 2022-04-13 | Інсайт Холдинґс Корпорейшн | Заміщені трициклічні сполуки як інгібітори fgfr |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| WO2014033630A1 (en) | 2012-08-31 | 2014-03-06 | Novartis Ag | Novel aminothiazole carboxamides as kinase inhibitors |
| WO2014033631A1 (en) | 2012-08-31 | 2014-03-06 | Novartis Ag | N-(3-pyridyl) biarylamides as kinase inhibitors |
| EP2900657B1 (en) * | 2012-09-26 | 2020-03-11 | F.Hoffmann-La Roche Ag | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| EP2914591B1 (en) | 2012-11-03 | 2017-10-11 | Boehringer Ingelheim International GmbH | Inhibitors of cytomegalovirus |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US20150336960A1 (en) | 2012-12-19 | 2015-11-26 | Novartis Ag | Aryl-substituted fused bicyclic pyridazine compounds |
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| CA2897333C (en) | 2013-01-15 | 2021-07-06 | Incyte Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
| PT2953942T (pt) | 2013-02-06 | 2018-01-17 | Bayer Cropscience Ag | Derivados de pirazol substituídos com halogéneo como agentes pesticidas |
| MY181497A (en) | 2013-04-19 | 2020-12-23 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| CR20160135A (es) | 2013-08-23 | 2016-08-05 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de cinasas pim |
| JP6487426B2 (ja) | 2013-10-17 | 2019-03-20 | ダウ アグロサイエンシィズ エルエルシー | 有害生物防除化合物の調製法 |
| EP3057431A4 (en) | 2013-10-17 | 2017-04-05 | Dow AgroSciences LLC | Processes for the preparation of pesticidal compounds |
| CN105636446B (zh) | 2013-10-17 | 2018-07-13 | 美国陶氏益农公司 | 制备杀虫化合物的方法 |
| MX2016004942A (es) | 2013-10-17 | 2016-06-28 | Dow Agrosciences Llc | Procesos para la preparacion de compuestos plaguicidas. |
| JP2016536295A (ja) | 2013-10-17 | 2016-11-24 | ダウ アグロサイエンシィズ エルエルシー | 有害生物防除性化合物の製造方法 |
| CA2926095A1 (en) | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| CN105636440A (zh) | 2013-10-17 | 2016-06-01 | 美国陶氏益农公司 | 制备杀虫化合物的方法 |
| EP3060046A4 (en) | 2013-10-22 | 2017-07-26 | Dow AgroSciences LLC | Pesticidal compositions and related methods |
| WO2015061147A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
| CN105848481A (zh) | 2013-10-22 | 2016-08-10 | 美国陶氏益农公司 | 协同杀虫组合物和相关方法 |
| EP3060047A4 (en) | 2013-10-22 | 2017-04-26 | Dow AgroSciences, LLC | Pesticidal compositions and related methods |
| KR20160074635A (ko) | 2013-10-22 | 2016-06-28 | 다우 아그로사이언시즈 엘엘씨 | 상승작용적 살충 조성물 및 관련 방법 |
| CA2927195A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
| AR098096A1 (es) | 2013-10-22 | 2016-05-04 | Dow Agrosciences Llc | Composiciones plaguicidas sinérgicas y métodos relacionados |
| CA2926101C (en) | 2013-10-22 | 2022-05-31 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
| KR20160074582A (ko) | 2013-10-22 | 2016-06-28 | 다우 아그로사이언시즈 엘엘씨 | 상승작용적 살충 조성물 및 관련 방법 |
| CN105658062A (zh) | 2013-10-22 | 2016-06-08 | 美国陶氏益农公司 | 协同杀虫组合物和相关方法 |
| EP3060051A4 (en) | 2013-10-22 | 2017-04-05 | Dow AgroSciences LLC | Synergistic pesticidal compositions and related methods |
| CA2926345A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
| AU2014340430B2 (en) | 2013-10-22 | 2017-05-25 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
| TW201519782A (zh) | 2013-10-22 | 2015-06-01 | Dow Agrosciences Llc | 殺蟲組成物及相關方法（五） |
| KR20160074633A (ko) | 2013-10-22 | 2016-06-28 | 다우 아그로사이언시즈 엘엘씨 | 상승작용적 살충 조성물 및 관련 방법 |
| RU2016119571A (ru) | 2013-10-22 | 2017-11-28 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Синергетические пестицидные композиции и связанные с ними способы |
| KR102286233B1 (ko) | 2013-10-22 | 2021-08-06 | 코르테바 애그리사이언스 엘엘씨 | 살충 조성물 및 관련 방법 |
| TW201609651A (zh) * | 2013-11-12 | 2016-03-16 | 陶氏農業科學公司 | 用於氟化化合物之過程（一） |
| KR20160127140A (ko) | 2014-03-18 | 2016-11-02 | 에프. 호프만-라 로슈 아게 | 옥세판-2-일-피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법 |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| BR112017000418A2 (pt) | 2014-07-31 | 2017-11-07 | Dow Agrosciences Llc | processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina |
| EP3186230A4 (en) | 2014-07-31 | 2018-01-10 | Dow AgroSciences, LLC | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
| CA2954345A1 (en) | 2014-07-31 | 2016-02-04 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
| EP3183238A4 (en) | 2014-08-19 | 2018-01-10 | Dow AgroSciences LLC | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
| BR112017004613A2 (pt) | 2014-09-12 | 2017-12-05 | Dow Agrosciences Llc | processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
| RS62639B1 (sr) | 2015-07-06 | 2021-12-31 | Alkermes Inc | Hetero-halo inhibitori histonskih deacetilaza |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
| WO2018098413A1 (en) * | 2016-11-28 | 2018-05-31 | Bristol-Myers Squibb Company | Pyrimidine carboxamides as gsk-3 inhibitors |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| US10100033B2 (en) | 2016-12-29 | 2018-10-16 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| WO2018125817A1 (en) | 2016-12-29 | 2018-07-05 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| MD3570834T2 (ro) | 2017-01-11 | 2022-04-30 | Alkermes Inc | Inhibitori biciclici ai histon deacetilazei |
| WO2018217766A1 (en) | 2017-05-22 | 2018-11-29 | Whitehead Institute For Biomedical Research | Kcc2 expression enhancing compounds and uses thereof |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| JP7152471B2 (ja) | 2017-08-07 | 2022-10-12 | ロダン・セラピューティクス，インコーポレーテッド | ヒストン脱アセチル化酵素の二環阻害剤 |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| WO2019200254A1 (en) | 2018-04-13 | 2019-10-17 | Tolero Pharmaceuticals, Inc. | Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer |
| PE20210919A1 (es) | 2018-05-04 | 2021-05-19 | Incyte Corp | Sales de un inhibidor de fgfr |
| KR102831570B1 (ko) * | 2018-05-04 | 2025-07-10 | 레미디 플랜, 인크. | 암 줄기 세포를 표적화하는 암 치료 |
| BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
| CA3127502A1 (en) | 2019-02-12 | 2020-08-20 | Sumitomo Dainippon Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| MA55593A (fr) | 2019-04-11 | 2022-02-16 | Janssen Pharmaceutica Nv | Cycles pyridine contenant des dérivés servant d'inhibiteurs de malt1 |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021020362A1 (ja) * | 2019-07-29 | 2021-02-04 | 武田薬品工業株式会社 | 複素環化合物 |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN120302975A (zh) | 2022-10-31 | 2025-07-11 | 住友制药美国公司 | 治疗骨髓增生性肿瘤的pim1抑制剂 |
| KR20250110929A (ko) | 2022-12-02 | 2025-07-21 | 뉴모라 테라퓨틱스, 인코포레이티드 | 신경학적 장애를 치료하는 방법 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070254894A1 (en) * | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
| WO2008054749A1 (en) * | 2006-10-31 | 2008-05-08 | Schering Corporation | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
| WO2008054701A1 (en) * | 2006-10-31 | 2008-05-08 | Schering Corporation | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
| WO2009014637A2 (en) * | 2007-07-19 | 2009-01-29 | Schering Corporation | Heterocyclic amide compounds as protein kinase inhibitors |
| WO2009058728A1 (en) * | 2007-10-29 | 2009-05-07 | Schering Corporation | Thiazole derivatives as protein kinase inhibitors |
| CN101679266A (zh) * | 2007-03-01 | 2010-03-24 | 诺瓦提斯公司 | Pim激酶抑制剂及其应用方法 |
| WO2011029802A1 (en) * | 2009-09-08 | 2011-03-17 | F. Hoffmann-La Roche Ag | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223526A (en) * | 1991-12-06 | 1993-06-29 | Monsanto Company | Pyrazole carboxanilide fungicides and use |
| GB0412072D0 (en) * | 2004-05-28 | 2004-06-30 | Syngenta Participations Ag | Chemical compounds |
| KR20090004976A (ko) * | 2006-04-19 | 2009-01-12 | 아스테라스 세이야쿠 가부시키가이샤 | 아졸카르복사미드 유도체 |
| WO2009020198A1 (ja) * | 2007-08-03 | 2009-02-12 | Kinopharma, Inc. | 抗ｄｎａウイルス作用を有するアニリン誘導体 |
| PE20091577A1 (es) * | 2008-03-03 | 2009-11-05 | Novartis Ag | Inhibidores de cinasa pim y metodos para su uso |
| BRPI0918268B1 (pt) * | 2008-09-02 | 2021-08-03 | Novartis Ag | Derivados de picolinamida, seu uso, e composição farmacêutica |
-
2011
- 2011-07-04 EP EP11729624.4A patent/EP2590968A1/en not_active Withdrawn
- 2011-07-04 CN CN2011800335423A patent/CN103080106A/zh active Pending
- 2011-07-04 US US13/807,993 patent/US20130109682A1/en not_active Abandoned
- 2011-07-04 JP JP2013517331A patent/JP2013530199A/ja active Pending
- 2011-07-04 WO PCT/EP2011/061198 patent/WO2012004217A1/en not_active Ceased
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070254894A1 (en) * | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
| WO2008054749A1 (en) * | 2006-10-31 | 2008-05-08 | Schering Corporation | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
| WO2008054701A1 (en) * | 2006-10-31 | 2008-05-08 | Schering Corporation | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
| CN101679266A (zh) * | 2007-03-01 | 2010-03-24 | 诺瓦提斯公司 | Pim激酶抑制剂及其应用方法 |
| WO2009014637A2 (en) * | 2007-07-19 | 2009-01-29 | Schering Corporation | Heterocyclic amide compounds as protein kinase inhibitors |
| WO2009058728A1 (en) * | 2007-10-29 | 2009-05-07 | Schering Corporation | Thiazole derivatives as protein kinase inhibitors |
| WO2011029802A1 (en) * | 2009-09-08 | 2011-03-17 | F. Hoffmann-La Roche Ag | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
Non-Patent Citations (2)
| Title |
|---|
| TERENCE A. KELLY，等: ""Novel Non-nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase. 5. 4-Substituted and 2,4-Disubstituted Analogs of Nevirapine"", 《J. MED. CHEM.》 * |
| UPENDER VELAPARTHI，等: ""Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R)"", 《BIOORG. MED. CHEM. LETT.》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106795151A (zh) * | 2014-08-06 | 2017-05-31 | 诺华股份有限公司 | 蛋白激酶c抑制剂和它们的使用方法 |
| US10508101B2 (en) | 2014-08-06 | 2019-12-17 | Novartis Ag | Protein kinase C inhibitors and methods of their use |
| CN106795151B (zh) * | 2014-08-06 | 2021-05-07 | 诺华股份有限公司 | 蛋白激酶c抑制剂和它们的使用方法 |
| US11059804B2 (en) | 2014-08-06 | 2021-07-13 | Novartis Ag | Protein kinase C inhibitors and methods of their use |
| US11505541B2 (en) | 2014-08-06 | 2022-11-22 | Novartis Ag | Protein kinase C inhibitors and methods of their use |
| CN110713476A (zh) * | 2019-11-07 | 2020-01-21 | 河南中烟工业有限责任公司 | 一种2,3-二氢-3,5-二羟基-6-甲基-4h-吡喃-4-酮的合成方法 |
| CN110790737A (zh) * | 2019-11-07 | 2020-02-14 | 河南中烟工业有限责任公司 | 一种2,3-二氢-3,5-二羟基-6-乙基-4h-吡喃-4-酮的制备方法 |
| CN110790737B (zh) * | 2019-11-07 | 2022-07-22 | 河南中烟工业有限责任公司 | 一种2,3-二氢-3,5-二羟基-6-乙基-4h-吡喃-4-酮的制备方法 |
| CN110713476B (zh) * | 2019-11-07 | 2022-07-26 | 河南中烟工业有限责任公司 | 一种2,3-二氢-3,5-二羟基-6-甲基-4h-吡喃-4-酮的合成方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2590968A1 (en) | 2013-05-15 |
| JP2013530199A (ja) | 2013-07-25 |
| US20130109682A1 (en) | 2013-05-02 |
| WO2012004217A1 (en) | 2012-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103080106A (zh) | 用作激酶抑制剂的环醚化合物 | |
| CN102203079B (zh) | 作为激酶抑制剂的吡啶甲酰胺衍生物 | |
| CN102203075B (zh) | 二环激酶抑制剂 | |
| JP6204462B2 (ja) | キナーゼ阻害剤としての新規環置換ｎ−ピリジニルアミド | |
| CN103402984A (zh) | 新的激酶抑制剂 | |
| TW202523663A (zh) | KRas G12D抑制劑 | |
| CN119241481A (zh) | 作为yap/taz-tead蛋白-蛋白相互作用抑制剂的联芳基衍生物 | |
| KR102339227B1 (ko) | Gsk-3 억제제 | |
| CN103429572A (zh) | 作为激酶抑制剂的四取代的环己基化合物 | |
| KR20150058257A (ko) | 환형 에터 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 이의 사용 방법 | |
| WO2014033631A1 (en) | N-(3-pyridyl) biarylamides as kinase inhibitors | |
| CN114144230A (zh) | 作为eed和prc2调节剂的大环唑并吡啶衍生物 | |
| CN119119033A (zh) | 吡唑并吡啶酮化合物 | |
| CN120957998A (zh) | 作为MTA-协同PRMT5抑制剂的5-氨基-6,8-二氢-1H-呋喃并[3,4-d]吡咯并[3,2-b]吡啶-2-甲酰胺衍生物 | |
| CN120731203A (zh) | 作为mettl3抑制剂的哌啶衍生物 | |
| HK40010063A (en) | Pyrido five-element aromatic ring compound, preparation method therefor and use thereof | |
| HK1162022B (en) | Picolinamide derivatives as kinase inhibitors | |
| HK1210155B (zh) | 含氮杂环化合物或其盐 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Basel Applicant after: Novartis Ag Address before: Basel Applicant before: Novartis AG |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: NOVARTIS AG TO: NOVARTIS CO., LTD. |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130501 |